公开(公告)号：US20230131867A1

公开(公告)日：2023-04-27

申请号：US17947716

申请日：2022-09-19

申请人： SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： David GIN ,  Michelle ADAMS ,  Kai DENG ,  Philip LIVINGSTON ,  Govindaswami RAGUPATHI ,  Eric CHEA ,  Alberto FERNANDEZ-TEJADA ,  Lars Ulrik NORDSTROEM ,  William WALKOWICZ ,  Jeffrey GARDNER ,  Derek TAN

IPC分类号： C07H15/256 ,  C07H13/08 ,  A61K31/7024 ,  A61K31/704 ,  C07H15/24 ,  A61K39/385

摘要： The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.

公开(公告)号：US20230111095A1

公开(公告)日：2023-04-13

申请号：US17769607

申请日：2020-09-25

申请人： Cansino Biologics Inc.

发明人： Haomeng WANG ,  Qiaoling YAN ,  Shoubai CHAO ,  Huhua MAO ,  Tao ZHU

IPC分类号： A61K39/385 ,  A61P31/04 ,  A61K39/09

摘要： The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.

公开(公告)号：US11612651B2

公开(公告)日：2023-03-28

申请号：US17738548

申请日：2022-05-06

申请人： DEFENCE THERAPEUTICS INC.

发明人： Simon Beaudoin

IPC分类号： A61K47/50 ,  A61P31/14 ,  A61K39/385 ,  A61K47/54 ,  A61K47/64 ,  A61K39/00

摘要： Immunogen enhancers for admixture with an antigen of interest are described herein. The enhancers generally comprise a steroid acid and/or a steroid acid-peptide conjugate in an amount sufficient to improve or modify the adaptive immune response to antigens admixed therewith. In embodiments, the steroid acid may be a bile acid and the peptide may comprise one or more functional domains, such as a nuclear localization signal, which may facilitate antigen-presentation and/or antigen cross-presentation, thereby triggering improved cellular immunity, or improved cellular and humoral immunity, against the antigen.

公开(公告)号：US20230062987A1

公开(公告)日：2023-03-02

申请号：US17934781

申请日：2022-09-23

申请人： Glaxosmithkline Biologicals S.A. ,  Janssen Pharmaceuticals, Inc.

发明人： Jan Theunis POOLMAN ,  Bert JACQUEMYN ,  Darren Robert ABBANAT ,  Patricia Ibarra YON ,  Peter Wilhelmus Maria HERMANS ,  Michael Thomas KOWARIK ,  Michael Lukas WETTER ,  Stefan Jochen KEMMLER ,  Micha Andres HÄUPTLE ,  Veronica Gambillara FONCK ,  Manuela MALLY

IPC分类号： A61K39/108 ,  A61K47/64 ,  C08B37/00 ,  A61P31/04 ,  A61K39/385

摘要： Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

公开(公告)号：US11564988B2

公开(公告)日：2023-01-31

申请号：US16564322

申请日：2019-09-09

申请人： David A. Scheinberg ,  Michael R. McDevitt ,  Christophe Antczak ,  Debjit Chattopadhyay ,  Rena May ,  Jon Njardarson ,  Mark Reid Phillips

发明人： David A. Scheinberg ,  Michael R. McDevitt ,  Christophe Antczak ,  Debjit Chattopadhyay ,  Rena May ,  Jon Njardarson ,  Mark Reid Phillips

IPC分类号： A61K47/52 ,  A61K39/385 ,  A61K47/64 ,  A61K47/65 ,  A61K51/12 ,  B82Y30/00 ,  B82Y40/00 ,  C01B32/174 ,  A61K47/69 ,  C01B32/176 ,  B82Y5/00

摘要： The present invention provides soluble single wall nanotube (SWNT) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble SWNT via a DNA or other oligomer platform attached to the SWNT. These soluble SWNT constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble SWNT constructs.

公开(公告)号：US11547752B2

公开(公告)日：2023-01-10

申请号：US16369933

申请日：2019-03-29

申请人： BIOLOGICAL E LIMITED

发明人： Ramesh Venkat Matur ,  Rajan Sriraman ,  Deviprasanna Chakka ,  Satyam Naidu Sureddi ,  Rajendar Burki ,  Sreenivasa Rao Ganti ,  Narender Dev Mantena ,  Mahima Datla

IPC分类号： A61K39/09 ,  A61K39/39 ,  A61K39/385 ,  A61K9/00 ,  A61K39/00

摘要： The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

公开(公告)号：US11534484B2

公开(公告)日：2022-12-27

申请号：US16709999

申请日：2019-12-11

申请人： AC Immune SA

发明人： Markus Mandler ,  Harald Weninger ,  Radmila Santic ,  Edith Kopinits

IPC分类号： A61K38/00 ,  C07K7/00 ,  C07K4/00 ,  C07K14/00 ,  A61K49/00 ,  A61K38/17 ,  C07K14/47 ,  C07K14/475 ,  C07K14/48 ,  C07K19/00 ,  C07K14/435 ,  A61K39/00 ,  C07K16/42 ,  A61K47/64 ,  A61K9/00 ,  A61K47/02 ,  A61K39/395 ,  A61K39/385 ,  G01N33/68 ,  C07K16/18 ,  C07K7/06 ,  C07K7/08 ,  A61P25/28 ,  A61P25/16 ,  A61K31/00 ,  A61K47/42 ,  A61K47/69

摘要： A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.

公开(公告)号：US20220378897A1

公开(公告)日：2022-12-01

申请号：US17814281

申请日：2022-07-22

申请人： Pfizer Inc.

发明人： Jianxin Gu ,  Rajesh Kumar Kainthan ,  Jin-Hwan Kim ,  Avvari Krishna Prasad ,  Yu-Ying Yang

IPC分类号： A61K39/09 ,  A61K39/385 ,  A61K39/39

摘要： The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

公开(公告)号：US11504422B2

公开(公告)日：2022-11-22

申请号：US15242626

申请日：2016-08-22

申请人： NATIONAL CHENG KUNG UNIVERSITY

发明人： Yee-Shin Lin ,  Yu-Hung Chen

IPC分类号： A61K47/34 ,  A61K47/36 ,  A61K39/00 ,  A61K39/12 ,  C12N7/00 ,  A61K39/385 ,  B82Y5/00

摘要： The present invention relates to a biodegradable nanocomplex. The biodegradable nanocomplex comprises a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside. The first electrically charged substance and the carried substance have the same electrical polarity, and the biodegradable nanocomplex has a nonuniformally and positively charge distribution along a radial direction thereof. The nonuniformally and positively charge distribution comprises a first electrically charged portion having substantially electrical neutrality, a second electrically charged portion surrounding the first electrically charged portion, and a third electrically charged portion surrounding the second electrically charged portion, in which the third electrically charged portion comprises an outermost surface of the biodegradable nanocomplex, thereby modulating the carried substance towards the desired immune responses via the nonuniformally and positively charge distribution.

公开(公告)号：US20220362391A1

公开(公告)日：2022-11-17

申请号：US17815681

申请日：2022-07-28

申请人： Zoetis Services LLC

发明人： Gary Francis Bammert ,  Steven Alan Dunham

IPC分类号： A61K47/64 ,  A61K39/00 ,  A61K38/12 ,  A61K39/385 ,  G01N33/68

摘要： The present invention provides a method of determining the identity and/or amount of an anti-IL-31 antibody in a sample. Such a method includes incubating a sample comprising an anti-IL-31 antibody with at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and determining the identity and/or quantity of the anti-IL-31 in the sample.